Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 billion. Blueprint specializes in systemic mastocytosis and other ...

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with Regeneron Pharmaceuticals, marking a significant advance in COPD ...

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750 million ...

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750 million ...

Sanofi successfully prices €1.5 billion bond issue. Paris, June 17, 2025- Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:.

See the latest Sanofi SA ADR stock price (SNY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

BofA Securities lowered its price target on Sanofi (SAN:FP) (NASDAQ: SNY) to EUR8.40 from EUR8.48 on Tuesday, while maintaining a Buy rating on the French pharmaceutical company’s stock. With a ...

New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously via an on-body injector in relapsed or refractory multiple myeloma support the potential use ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp ...